The Department of Industrial Technology (DoIT) of the Ministry of Economic Affairs (MOEA) convened three research foundations-ITRI (Industrial Technology Research Institute), FIRDI (Food Industry Research and Development Institute), and the Development Center for Biotechnology (DCB)-to establish the DoIT pavilion, which held its opening ceremony at BIO Asia-Taiwan 2025. The pavilion showcases 12 innovative technological achievements in health maintenance, disease prevention, and treatment, highlighting Taiwan's capabilities in biomedical research and development while injecting new momentum into the health industry. Key exhibit technologies include the "Smart Processing & Equipment Integration for Plant-Based Drinks," designed for the elderly; the "Long-Lasting Immunity of CD40 Ligand Ribonucleic Acid Vaccine Adjuvant," developed to extend vaccine effectiveness; and the "Novel Selective FPR1 Antagonist," which reduces side effects while improving therapeutic outcomes.
Senior Technical Specialist of the Department of Industrial Technology (DoIT), Mr. Tai Chien-Cheng , indicated that in the face of global political and economic uncertainties, pharmaceuticals have become essential strategic commodities vital to public well-being and safety. Taiwan's strengths in research and development (R&D), regulatory frameworks, and manufacturing processes position it as a reliable partner for international pharmaceutical companies. To enhance global integration and expand cooperation, Taiwan should improve collaboration across both upstream and downstream industries, thereby increasing technical density and strengthening global competitiveness. He advocated for DoIT to continue connecting foundational resources and implementing supportive policies for R&D funding and tools to facilitate industrial advancement. The pavilion symbolizes the long-term commitment of research institutions to the "Three-Stage, Five-Level Prevention" framework, linking applications from "precision medicine" to "palliative care," and showcasing the government's proactive efforts in realizing the "Healthy Taiwan" policy.
In addition, several breakthroughs driven by or related to artificial intelligence (AI) are highlighted among the 12 innovative technologies showcased in the pavilion.
ITRI presents "Tumor-Derived Exosomes Enrichment and Detection Platform", and "One-Stop Exosome Isolation and Characterization Services". FIRDI showcases "Intelligent Preparation of Nutritional Beverages" in AI-powered biomedicine research and development.
ITRI's "In Vivo Delivery of mRNA Encoding CAR to Macrophages for Solid Tumor Therapy" and "An Eye Drop Product for Dry AMD Treatment". DCB showcases "Rejuvenating CAR-T Cells Through the Secretion of Antibodies Targeting Immunosuppressive Axis" and "NTSR1-ADC: A Novel Therapeutics for Head and Neck Cancer" for cancer and ophthalmic conditions. These technologies highlight the progress in therapeutic drug development and the emergence of new treatment breakthroughs.
Additionally, FIRDI contributes its technical expertise through the development of "Plant-based animal fat alternative technology" and "Microorganisms in the Modification of Food Texture and Flavor". These innovations aim to redefine the texture and quality of plant-based meats, infusing the plant-based industry with dynamic advancements.
